MaxCyte joins Alliance for mRNA Medicines

Cell engineering company MaxCyte announced its membership in the Alliance for mRNA Medicines (AMM) as a founding member on Thursday.

The AIM-traded firm described AMM as an organisation committed to advancing mRNA and next-generation encoding RNA therapeutics and vaccines for the betterment of patients, public health, and society.

It said AMM’s mission was to propel the future of mRNA medicines, enhance patient well-being, and contribute to scientific knowledge by uniting industry leaders, innovators, scientists, and critical stakeholders in the mRNA field.

MaxCyte was joining 30 other founding members, including biotechnology, biopharma, life sciences companies, and educational institutions.

The inauguration of AMM took place in early November during the 11th International mRNA Health Conference in Berlin.

AMM and its advisors aimed to champion policies that foster innovation and funding, establish regulatory and reimbursement standards, support manufacturing, and facilitate patient access to mRNA medicines.

That, it said, would be accomplished through proactive engagement with governments, policymakers, regulators, and other stakeholders across North America, Europe, and the Asia Pacific region.

“We proudly join our colleagues in advancing AMM’s mission as we recognise the significant potential of mRNA scientific innovation to transform human health,” said president and chief executive officer Doug Doerfler.

“Our versatile, leading electroporation platform continues to provide scientific innovators with a powerful and flexible transfection method to accelerate the development of critical medicines and vaccines.

“We remain steadfast in our commitment to enable development of new applications for mRNA technology.”

At 1359 GMT, shares in MaxCyte were up 10.64% at 309.8p.

Reporting by Josh White for Sharecast.com.